Hepatocellular carcinoma (HCC) has an increasing incidence and global mortality burden. Diagnosis and management of HCC has improved over the years, and innovative molecular tests are emerging as promising biomarkers for prognosis and response prediction. Conventional circulating protein biomarkers, such as alpha-fetoprotein, are widely used but have limited sensitivity and specificity. Liquid biopsy approaches rely on the detection and characterization of additional blood-borne analytes—including circulating tumor-derived DNA genomic or epigenomic features, exosomes, circulating tumor cells, and others. These methods—potentially in combination with conventional blood-based analytes—have the potential to significantly improve early detection, prognostication, and treatment monitoring. In this review, we highlight recent nongenomic blood-based liquid biopsy approaches and their clinical applications in HCC.
Purpose: Although immunotherapy regimens have significantly improved treatment options for patients with advanced hepatocellular carcinoma (HCC), the optimal use of these regimens in earlier disease stages remains poorly defined. Patients and Methods: We conducted a single-institution, single-arm pilot study (NCT04857684) of neoadjuvant stereotactic body radiotherapy (SBRT) followed by 2 cycles of atezolizumab plus bevacizumab and subsequent surgical resection in patients with initially resectable HCC (n = 8). The primary endpoint was safety as defined by the proportion of patients with grade 3 to 4 treatment-related adverse events (trAE) by Common Terminology Criteria for Adverse Events v5.0. Furthermore, we dissected the detailed remodeling of the tumor immune microenvironment following treatment using single-cell resolution spatial transcriptomic method. Results: Only 1 patient experienced a grade 3 trAE. Seven of 8 patients proceeded to surgery, and all achieved margin-negative (R0) resection; 1 patient did not proceed because of subsequent disagreement of resectability. One patient achieved a pathologic complete response, and all resected patients were relapse-free at data cutoff (median follow-up, 16.3 months; range, 2.1–19.9). Compared with unmatched treatment-naïve HCC specimens, posttreatment specimens showed significantly higher anticancer immune infiltration, including organized peritumoral aggregates. Immune infiltration and its proximity to tumor cells correlated with preoperative radiographic response. Conclusions: This study provides proof of concept that neoadjuvant SBRT and immunotherapy is safe and provides a clear rationale for additional prospective clinical studies utilizing this strategy.
Supplementary Table S8 from Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment
Supplementary Table S1 from Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment